Anzeige
Mehr »
Donnerstag, 09.10.2025 - Börsentäglich über 12.000 News
Kursrakete 2025: CiTech präsentiert sich u.a. mit DroneShield neben Palantir & Rheinmetall - welche News sind zu erwarten?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H9G8 | ISIN: US24823R1059 | Ticker-Symbol: 4DN
Tradegate
09.10.25 | 11:03
13,355 Euro
-0,89 % -0,120
1-Jahres-Chart
DENALI THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
DENALI THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
13,36013,62514:47
13,36013,62514:47

Aktuelle News zur DENALI THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08.09.Cantor Fitzgerald reiterates Overweight rating on Denali Therapeutics stock43
12.08.DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '2641
DENALI THERAPEUTICS Aktie jetzt für 0€ handeln
11.08.Denali Therapeutics Inc. - 10-Q, Quarterly Report2
11.08.Denali Therapeutics Inc.: Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights3.218Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launchDNL126 accelerated approval...
► Artikel lesen
08.07.DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review23
07.07.Denali Therapeutics stock gains as FDA grants priority review for Hunter syndrome drug9
07.07.FDA accepts priority review for Denali's Hunter syndrome therapy2
07.07.Denali Therapeutics Inc. - 8-K, Current Report3
23.06.Denali Therapeutics-Aktie vor Katalysator: FDA-Entscheidung steht bevor23
23.06.Denali Therapeutics stock poised for catalyst as FDA decision nears2
03.06.Denali Therapeutics Inc. - 8-K, Current Report6
27.05.Stifel bekräftigt Kaufempfehlung für Denali Therapeutics mit Kursziel von 37 US-Dollar12
27.05.Stifel maintains Buy on Denali Therapeutics stock, $37 target1
08.05.Denali Therapeutics shares fall after price target cut to $328
06.05.Denali Therapeutics Inc.: Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome286SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided business...
► Artikel lesen
02.04.Denali Therapeutics Inc.: Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 ...279Rolling submission of BLA initiated for tividenofusp alfa; preparations ongoing for potential U.S. commercial launch in late 2025 or early 2026Alignment through recent interactions with CDER on path...
► Artikel lesen
06.02.Denali Therapeutics Inc.: Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa293Long-term data demonstrate that robust reductions and normalization in key biomarkers from baseline were maintained over time with continued improvement in hearing, cognition and adaptive behaviorLong-term...
► Artikel lesen
06.01.Denali Therapeutics Inc.: Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial224Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not met at 24 weeksOverall, DNL343 was found to be safe...
► Artikel lesen
05.12.24Denali Therapeutics Inc.: Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease199SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational...
► Artikel lesen
06.11.24Denali Therapeutics Inc.: Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights394SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2024, and provided...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2